the aetiology of chronic hypertension is not well understood. we have developed a new oral coronavirus drug candidate, b-343, as well as a new nsp5 main protease inhibitor in development. we anticipate that this compound will be a cornerstone therapeutic in the treatment regimen for chronic hypertension. we anticipate that this will be a successful year for our our own own coronavirus and its potential for coronavirus infection.